DOI:
10.1055/s-00050348
Indian Journal of Medical and Paediatric Oncology
LinksClose Window
References
Buzdar AU, Suman VJ, Meric-Bernstam F. et al.
American College of Surgeons Oncology Group investigators. Fluorouracil, epirubicin, and cyclophosphamide (FEC-75) followed by paclitaxel plus trastuzumab versus paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab as neoadjuvant treatment for patients with HER2-positive breast cancer (Z1041): a randomised, controlled, phase 3 trial.
Lancet Oncol 2013;
14 (13) 1317-1325
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.